EMEA-002028-PIP01-16-M01
Key facts
| Invented name |
Imfinzi
|
| Active substance |
durvalumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0256/2019
|
| PIP number |
EMEA-002028-PIP01-16-M01
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 8553 27591 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|